AbbVie is a global, research-driven biopharmaceutical company dedicated to tackling some of the world's toughest health challenges and delivering innovative solutions that transform lives. After originating from Abbott Laboratories, a pharmaceutical company founded in 1888 by Dr. Wallace Calvin Abbott and recognised as a leader in healthcare, AbbVie was launched in 2013 as a separate entity dedicated to pioneering biotechnology. The name "AbbVie" reflects a combination of Abbott's legacy and the Latin root "vie," which means "life."
AbbVie focuses on several key therapeutic areas, including immunology (addressing autoimmune diseases in rheumatology, gastroenterology, and dermatology), neurology, hepatitis C, and onco-haematology. In 2020, AbbVie broadened its portfolio by acquiring Allergan Aesthetics, thereby enhancing its range of products in the fields of aesthetics and eye care. In 2024, AbbVie's acquisition of Cerevel Therapeutics significantly strengthened its capabilities in neuroscience. Furthermore, by incorporating biotechnology from ImmnoGen, AbbVie expanded into the area of solid tumors.
In Bulgaria, AbbVie employs nearly 100 professionals whose daily collaboration and expertise contribute to the company's rapid growth and success, making it one of the leading pharmaceutical companies in the region.
